PROQR THRAPEUTICS N V's ticker is PRQR and the CUSIP is N71542109. A total of 20 filers reported holding PROQR THRAPEUTICS N V in Q1 2017. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2022 | $0 | -100.0% | 1 | -100.0% | 0.00% | -100.0% |
Q4 2021 | $35,744,000 | -10.9% | 4,462,438 | -6.9% | 0.00% | 0.0% |
Q3 2021 | $40,120,000 | +25.3% | 4,793,273 | +0.9% | 0.00% | 0.0% |
Q2 2021 | $32,024,000 | +2.0% | 4,751,399 | -0.0% | 0.00% | 0.0% |
Q1 2021 | $31,410,000 | +7343.1% | 4,751,933 | +4632.2% | 0.00% | – |
Q4 2020 | $422,000 | -30.0% | 100,416 | -20.3% | 0.00% | – |
Q3 2020 | $603,000 | -79.4% | 125,916 | -73.8% | 0.00% | – |
Q2 2020 | $2,922,000 | -40.2% | 480,616 | -46.0% | 0.00% | -100.0% |
Q1 2020 | $4,887,000 | -58.2% | 890,216 | -24.5% | 0.00% | 0.0% |
Q4 2019 | $11,689,000 | +160.8% | 1,179,486 | +51.6% | 0.00% | 0.0% |
Q3 2019 | $4,482,000 | -36.7% | 778,186 | 0.0% | 0.00% | 0.0% |
Q2 2019 | $7,081,000 | -46.7% | 778,186 | -18.8% | 0.00% | -50.0% |
Q1 2019 | $13,291,000 | -22.1% | 958,286 | -11.4% | 0.00% | 0.0% |
Q4 2018 | $17,064,000 | +4.2% | 1,081,366 | +27.8% | 0.00% | 0.0% |
Q3 2018 | $16,376,000 | +842.8% | 846,313 | +255.7% | 0.00% | – |
Q2 2018 | $1,737,000 | +137.3% | 237,916 | 0.0% | 0.00% | – |
Q1 2018 | $732,000 | -4.6% | 237,916 | 0.0% | 0.00% | – |
Q4 2017 | $767,000 | -33.5% | 237,916 | 0.0% | 0.00% | – |
Q3 2017 | $1,154,000 | -6.7% | 237,916 | 0.0% | 0.00% | – |
Q2 2017 | $1,237,000 | +3.9% | 237,916 | 0.0% | 0.00% | – |
Q1 2017 | $1,190,000 | +2.1% | 237,916 | 0.0% | 0.00% | – |
Q4 2016 | $1,166,000 | -26.5% | 237,916 | 0.0% | 0.00% | – |
Q3 2016 | $1,587,000 | +37.8% | 237,916 | 0.0% | 0.00% | – |
Q2 2016 | $1,152,000 | -0.8% | 237,916 | 0.0% | 0.00% | – |
Q1 2016 | $1,161,000 | -94.1% | 237,916 | -89.5% | 0.00% | -100.0% |
Q4 2015 | $19,615,000 | -40.4% | 2,259,801 | 0.0% | 0.00% | -40.0% |
Q3 2015 | $32,925,000 | -12.6% | 2,259,801 | 0.0% | 0.01% | 0.0% |
Q2 2015 | $37,671,000 | -22.5% | 2,259,801 | +1.7% | 0.01% | -16.7% |
Q1 2015 | $48,602,000 | +2989.8% | 2,221,315 | +2959.7% | 0.01% | – |
Q4 2014 | $1,573,000 | +26.0% | 72,600 | 0.0% | 0.00% | – |
Q3 2014 | $1,248,000 | – | 72,600 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aquilo Capital Management, LLC | 748,861 | $6,815,000 | 2.37% |
Opus Point Partners Management, LLC | 138,461 | $1,260,000 | 1.86% |
RTW INVESTMENTS, LP | 3,722,950 | $33,879,000 | 1.81% |
Kerrisdale Advisers, LLC | 465,580 | $4,237,000 | 1.52% |
DAFNA Capital Management LLC | 261,521 | $2,380,000 | 0.90% |
SPHERA FUNDS MANAGEMENT LTD. | 470,000 | $4,277,000 | 0.58% |
Artal Group S.A. | 1,300,000 | $11,830,000 | 0.48% |
Orbimed Advisors | 1,382,502 | $12,581,000 | 0.20% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 56,000 | $511,000 | 0.19% |
ALTRINSIC GLOBAL ADVISORS LLC | 201,360 | $1,832,000 | 0.08% |